Register to attend
Description
The World Health Organisation (WHO) puts antimicrobial resistance (AMR) in the top 10 public health threats facing humanity as antibiotics become less effective against increasingly resistant bacteria. AMR is directly linked to 1.27 million deaths per year, contributes to another 5 million deaths, and could cause an estimated USD 1 trillion in additional healthcare costs annually (World Bank). The crisis disproportionately impacts children under the age of five, with mortality occurring primarily in low- and middle-income countries. The challenge is exacerbated as drug resistant infections multiply in conflict zones and are then transported into civilian populations. Tackling AMR is an issue of human rights. Yet, while mitigation requires collaborative and multi-stakeholder action, this so-called "silent pandemic" remains acutely underfunded.
Due to the urgent need to combat this global threat, the UN General Assembly (UNGA) is convening a second high-level meeting (HLM) on AMR in September, co-chaired by the governments of Malta and Barbados. The goal is to adopt a new political declaration to guide the collective efforts of Member States and other relevant stakeholders. However, reflecting on the eight commitments which came out of the first HLM on AMR in 2016, many of the barriers to implementation have been economic. In a world of constrained government budgets, increasing geopolitical tensions and armed conflict, how can the new HLM political declaration be funded and implemented into action?
Join us for a moderated panel discussion with lively audience participation to discuss the outcomes of the September UNGA high-level negotiations on AMR, and how policymakers, international organisations, patient organisations, and civil society can take action to support mitigation of this major global health risk.
Speakers
Announced soon
Organised by
The Global Health Centre's International Geneva Global Health Platform, and the Global Antibiotic Research & Development Partnership (GARDP).
